top of page

December 31, 2022. BEIJING, China.

Recently, the Company won the following significant project bids. Now they are published for investors’ reference.

The Board of Directors of the Company and each member of the Board of Directors guarantee that the contents of the public announcement contain no false or misleading statements or major omission, and they are jointly and severally liable for the truthfulness, accuracy and completeness of the said contents.







December 17, 2022. SAN FRANCISCO, US.

Through the Patient Registry, we expect to increase our understanding of the medical and assistive technology needs of individuals at a larger scale in order to thoughtfully design future clinical trials and neurotechnology devices that meet these individuals’ needs.

Over the last few years, we have worked with patient advocacy groups and a consumer advisory board consisting of individuals with spinal cord injury and their caregivers to guide product development and community engagement.


As an expansion of these efforts, we’ve launched a Patient Registry to learn more about individuals who want to contribute to this initiative and who may be interested in enrolling in future Neuralink clinical trials, when they become available.


Through the Patient Registry, we expect to increase our understanding of the medical and assistive technology needs of individuals at a larger scale in order to thoughtfully design future clinical trials and neurotechnology devices that meet these individuals’ needs.


To apply and participate in the Patient Registry you must be at least 18 years old, meet the age of majority in your state, and be a U.S. citizen or permanent resident with any of the following:


  1. Tetraplegia or tetraparesis (paralysis or severe weakness in all four limbs)

  2. Paraplegia (paralysis in at least two limbs)

  3. Vision loss

  4. Deafness

  5. Aphasia (inability to speak)

Participation in the Patient Registry is voluntary and you have the right to withdraw your consent at any time. To participate, you’ll have to complete the Patient Registry informed consent form, authorize Neuralink to access your medical records, and complete a questionnaire. There is no compensation nor anticipated benefit for participating in the Patient Registry; however, if you meet preliminary eligibility for a future Neuralink clinical trial you may be contacted with more information once it is available for enrollment.


Your participation in the Patient Registry will not enroll you or guarantee enrollment in any future Neuralink clinical trial. Moreover, you don’t need to participate in the Patient Registry in order to participate in future Neuralink clinical trials. Currently, Neuralink does not have any clinical trials available.


We want to build the future of brain-computer interfaces, and would like your help to build that future. With the right team, the potential applications for this technology are limitless!


Interested in applying to the Patient Registry or learning more? Visit Neuralink’s Patient Registry here.



September 18, 2022. NATIONAL HARBOR, Maryland USA.

Teaming agreement signed to add mission systems support for new Bell aircraft development

Bell Textron Inc., a Textron Inc. (NYSE: TXT) company, announced today it has entered into a teaming agreement with Sierra Nevada Corporation (SNC), a global aerospace and national security company, for Bell’s High-Speed Vertical Takeoff and Landing (HSVTOL) aircraft. As part of the collaboration, SNC will specifically support the design and development of mission systems for HSVTOL variants.



Bell’s HSVTOL vehicles blend the hover capability of a helicopter with the speed, range and survivability features of fighter aircraft, with low downwash hover capability and jet-like speeds of more than 400 kts. This family of scalable aircraft concepts is designed to carry out USAF and USSOCOM missions across the full spectrum of conflict and political scenarios, including personnel recovery, contested logistics and ISR/Strike.


“In an effort to advance technical maturity and deliver HSVTOL capability to warfighters sooner, Bell is assembling a team of industry-leading partners. We’re thrilled to have SNC onboard,” said Jason Hurst, vice president, Innovation, Bell. “We’ve made significant progress in Bell’s HSVTOL technology development in 2022, and we look forward to showing this progress in the upcoming year.”


“SNC is delighted to join the Bell’s HSVTOL development team, and we are already hard at work to deliver the visionary mission systems that Bell demands for their visionary aircraft,” says Derek Hess, vice president, strategic program business development at SNC. “Our nation’s warfighters will benefit from this HSVTOL program’s ground-breaking operational capabilities.”


Similar to Bell’s innovation development, SNC continues to leverage its mission systems expertise to explore dynamic new opportunities. SNC also supports Bell with additional mission systems expertise for the development of the Bell 360 Invictus for the U.S. Army’s Future Attack Reconnaissance Aircraft (FARA) competition.


Bell is currently executing its HSVTOL risk reduction effort and participating in the AFWERX HSVTOL Concept Challenge, a crowdsourcing effort for the United States Air Force (USAF) and United States Special Operations Command (USSOCOM). Bell is one of 11 companies from more than 200 challenge entrants selected to receive market research investments aimed at advancing HSVTOL technology.


Alexis Baird

Technology & Innovation

  • kbaird@bellflight.com

  • +1 817-487-1020


_edited.png

A socio-corporate media platform of highlights on company news and industry events. Opinions of interests are key for post-productions in support from ASR TV.

© 2025 Alexander Solomon Report 

HomeT&C Privacy PolicyCookie Policy │Modern Slavery

bottom of page